Ignite Creation Date:
2024-05-06 @ 3:13 AM
Last Modification Date:
2024-10-26 @ 11:30 AM
Study NCT ID:
NCT02238223
Status:
COMPLETED
Last Update Posted:
2014-09-12
First Post:
2014-09-11
Brief Title:
Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion Tablet
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Post Marketing Surveillance of Alesion Epinastine Hydrochloride Tablet
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study to investigate the safety and efficacy information of Alesion Tablet under the proper use in daily clinical practice after new treatment guideline for allergic rhinitis bronchial asthma eczema dermatitis urticaria pruritus prurigo and psoriasis vulgaris with itching
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None